Rea, Federico
Savaré, Laura
Valsassina, Valeria
Ciardullo, Stefano
Perseghin, Gianluca
Corrao, Giovanni
Mancia, Giuseppe
Funding for this research was provided by:
Ministero dell'Università e della Ricerca (H45J17000500006)
Università degli Studi di Milano - Bicocca
Article History
Received: 22 November 2022
Accepted: 27 February 2023
First Online: 10 March 2023
Change Date: 19 October 2023
Change Type: Update
Change Details: The CRUI-CARE TA funding note has been removed
Declarations
:
: According to Italian law, studies based entirely on registry data do not require approval from an ethics review board.
: Not applicable.
: Giovanni Corrao received research support from the European Community (EC), the Italian Medicines Agency (AIFA), Italian Ministry of Health, and the Italian Ministry of Education, University and Research (MIUR). He took part to a variety of projects that were funded by pharmaceutical companies (i.e., Novartis, GSK, Roche, AMGEN, BMS and Servier). He also received honoraria as member of Advisory. Giuseppe Mancia received honoraria for participation as speaker/chairman in national/international meetings from Bayer, Boehringer Ingelheim, CVRx, Daiichi Sankyo, Ferrer, Medtronic, Menarini Int., Merck, Novartis, Recordati and Servier. Other authors have no disclosures.